ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026
Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Toward multi-domain lung cancer research databases: opportunities and challenges from MCC-MELD.Journal of thoracic disease · 2026Article
Corrections and comments
- Commented on by
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe proportion of lung cancers affecting individuals who have never smoked is growing, with these cancers being prone to harbor mutations in the EGFR gene. Little is known about risk factors and prognostic indicators for EGFR-mutant cancers, with current research limited by the scarcity of datasets integrating genomic, clinical, and environmental data.
methodsWe created the Meyer Cancer Center Molecularly Enhanced Lung Cancer Database (MCC-MELD), including lung cancer cases from a large catchment area in New York City. We identified cases through linkage to our institution's cancer registry and a clinician-initiated, manually curated database. We linked all cases to the electronic health record and in-house tumor genomic testing results. We used natural language processing (NLP) to extract unstructured genomic testing results and detailed smoking history. We linked geocoded addresses to detailed area-level measures.
resultsMCC-MELD contains 9,573 patients with lung cancer diagnosed from 1988 to 2024, of whom 20% were non-Hispanic Asian, 14% were non-Hispanic Black, and 8% were Hispanic. We identified 1,092 (11.4%) EGFR-mutant cancers, with NLP identifying 397 cases not identified by structured data. NLP showed high accuracy in ascertaining EGFR status (97%) and quantitative smoking history variables (90%-98%). Never smokers made up 16% of the cases in MCC-MELD.
conclusionsMCC-MELD is an NLP-enhanced database containing clinical information, genomic testing results, and linkages to area-level data for patients with lung cancer from a diverse urban setting. IMPACT: This resource can facilitate studies on lung cancer risk factors, treatment patterns, and outcomes by EGFR and other driver mutation status.
Indexed as
Identifiers
41171411What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.